[Great risk of future problems for Swedish cancer care].

[Underutilization of anticancer agents--an example]. Lakartidningen (2011) 1.40

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol (2006) 2.89

[A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment]. Lakartidningen (2008) 1.93

A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55

Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol (2003) 1.53

Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38

Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer (2013) 1.30

Knowledge and understanding among cancer patients consenting to participate in clinical trials. Eur J Cancer (2008) 1.28

Health related quality of life in different states of breast cancer. Qual Life Res (2007) 1.24

Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res (2010) 1.13

Levels of knowledge and perceived understanding among participants in cancer clinical trials - factors related to the informed consent procedure. Clin Trials (2010) 1.12

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol (2008) 1.07

Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care (2007) 1.00

Cost of breast cancer in Sweden in 2002. Eur J Health Econ (2007) 0.96

The meaning of breast cancer. Acta Oncol (2003) 0.91

A review of breast cancer care and outcomes in Latin America. Oncologist (2013) 0.89

Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access. Hum Vaccin Immunother (2012) 0.87

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer (2012) 0.85

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat (2006) 0.83

Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. Acta Oncol (2010) 0.78

Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels. Acta Oncol (2011) 0.75

Audio-recorded information to patients considering participation in cancer clinical trials - a randomized study. Acta Oncol (2014) 0.75

[Pharmaceuticals can be cost-effective in the long run]. Lakartidningen (2010) 0.75